Search Results - "Giovannoni, Gavin"

Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm by Giovannoni, Gavin

“…The treatment of multiple sclerosis is evolving rapidly with 11 classes of disease-modifying therapies (DMTs). This article provides an overview of a new…”
Get full text

Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary by Giovannoni, Gavin

Get full text

Systematic review and meta-analysis of the association between Epstein–Barr virus, multiple sclerosis and other risk factors by Jacobs, Benjamin M, Giovannoni, Gavin, Cuzick, Jack, Dobson, Ruth

“…Background: Epstein–Barr virus (EBV) infection is thought to play a central role in the development of multiple sclerosis (MS). If causal, it represents a…”
Get full text

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis by Gold, Ralf, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Giovannoni, Gavin, Selmaj, Krzysztof, Tornatore, Carlo, Sweetser, Marianne T, Yang, Minhua, Sheikh, Sarah I, Dawson, Katherine T

“…In this randomized trial involving patients with multiple sclerosis, BG-12 (dimethyl fumarate) reduced clinical relapses, disability progression, and MRI…”
Get full text

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials by Kappos, Ludwig, Wolinsky, Jerry S, Giovannoni, Gavin, Arnold, Douglas L, Wang, Qing, Bernasconi, Corrado, Model, Fabian, Koendgen, Harold, Manfrini, Marianna, Belachew, Shibeshih, Hauser, Stephen L

“…Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA),…”
Get more information

Multiple sclerosis: risk factors, prodromes, and potential causal pathways by Ramagopalan, Sreeram V, DPhil, Dobson, Ruth, MRCP, Meier, Ute C, DPhil, Giovannoni, Gavin, Prof

“…Summary Multiple sclerosis (MS) is a common, complex neurological disease. The precise aetiology of MS is not yet known, although epidemiological data indicate…”
Get full text

Cognition and its relation to brain health in patients with MS: Response to letter by Hobart, Jeremy, Giovannoni, Gavin

Get full text

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study by Giovannoni, Gavin, Soelberg Sorensen, Per, Cook, Stuart, Rammohan, Kottil, Rieckmann, Peter, Comi, Giancarlo, Dangond, Fernando, Adeniji, Abidemi K, Vermersch, Patrick

“…Background: In the 2-year CLARITY study, cladribine tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in…”
Get full text

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies by Bar-Or, Amit, Pender, Michael P., Khanna, Rajiv, Steinman, Lawrence, Hartung, Hans-Peter, Maniar, Tap, Croze, Ed, Aftab, Blake T., Giovannoni, Gavin, Joshi, Manher A.

“…New treatments for multiple sclerosis (MS) focused on B cells have created an atmosphere of excitement in the MS community. B cells are now known to play a…”
Get full text

The COVID-19 pandemic and the use of MS disease-modifying therapies by Giovannoni, Gavin, Hawkes, Chris, Lechner-Scott, Jeannette, Levy, Michael, Waubant, Emmanuelle, Gold, Julian

Get full text

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis by Chitnis, Tanuja, Arnold, Douglas L, Banwell, Brenda, Brück, Wolfgang, Ghezzi, Angelo, Giovannoni, Gavin, Greenberg, Benjamin, Krupp, Lauren, Rostásy, Kevin, Tardieu, Marc, Waubant, Emmanuelle, Wolinsky, Jerry S, Bar-Or, Amit, Stites, Tracy, Chen, Yu, Putzki, Norman, Merschhemke, Martin, Gärtner, Jutta

“…In 215 patients with a median age of 16 years, fingolimod was superior to interferon beta-1a in reducing relapses of multiple sclerosis and the accumulation of…”
Get full text

Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom by Kuri, Ashvin, Jacobs, Benjamin Meir, Vickaryous, Nikki, Pakpoor, Julia, Middeldorp, Jaap, Giovannoni, Gavin, Dobson, Ruth

“…Epstein-Barr Virus (EBV) is a ubiquitous gamma-herpesvirus with which ~ 95% of the healthy population is infected. EBV infection has been implicated in a range…”
Get full text

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis by Montalban, Xavier, Hauser, Stephen L, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Comi, Giancarlo, de Seze, Jérôme, Giovannoni, Gavin, Hartung, Hans-Peter, Hemmer, Bernhard, Lublin, Fred, Rammohan, Kottil W, Selmaj, Krzysztof, Traboulsee, Anthony, Sauter, Annette, Masterman, Donna, Fontoura, Paulo, Belachew, Shibeshih, Garren, Hideki, Mairon, Nicole, Chin, Peter, Wolinsky, Jerry S

“…Patients with primary progressive MS who received the anti-CD20+ humanized antibody ocrelizumab were less likely to have clinical deterioration that was…”
Get full text

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study by Giovannoni, Gavin, Singer, Barry A, Issard, Delphine, Jack, Dominic, Vermersch, Patrick

“…Background: No evidence of disease activity (NEDA-3) is a patient-centric outcome increasingly used as the goal of multiple sclerosis treatment. Objective:…”
Get full text

Cladribine: mechanisms and mysteries in multiple sclerosis by Jacobs, Benjamin Meir, Ammoscato, Francesca, Giovannoni, Gavin, Baker, David, Schmierer, Klaus

“…ObjectivesThe aims of this manuscript were to review the evidence for the efficacy and safety of cladribine in multiple sclerosis (MS) and to review the…”
Get full text

Meta-analysis of early nonmotor features and risk factors for Parkinson disease by Noyce, Alastair J., Bestwick, Jonathan P., Silveira-Moriyama, Laura, Hawkes, Christopher H., Giovannoni, Gavin, Lees, Andrew J., Schrag, Anette

“…Objective: To evaluate the association between diagnosis of Parkinson disease (PD) and risk factors or early symptoms amenable to population‐based screening…”
Get full text

The Multiple Sclerosis Care Unit by Soelberg Sorensen, Per, Giovannoni, Gavin, Montalban, Xavier, Thalheim, Christoph, Zaratin, Paola, Comi, Giancarlo

“…Treatment of multiple sclerosis (MS) has become increasingly multifaceted and comprises not only a variety of disease-modifying drugs with different mechanism…”
Get full text

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers by Stuve, Olaf, Soelberg Soerensen, Per, Leist, Thomas, Giovannoni, Gavin, Hyvert, Yann, Damian, Doris, Dangond, Fernando, Boschert, Ursula

“…Background: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant clinical/imaging effects in patients with clinically isolated syndrome…”
Get full text

Extended dosing of monoclonal antibodies in multiple sclerosis by van Kempen, Zoé LE, Toorop, Alyssa A, Sellebjerg, Finn, Giovannoni, Gavin, Killestein, Joep

“…Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no…”
Get full text

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases by Clifford, David B, MD, DeLuca, Andrea, MD, Simpson, David M, MD, Arendt, Gabriele, MD, Giovannoni, Gavin, MBBCh, Nath, Avindra, MD

“…Summary Background Treatment of multiple sclerosis with natalizumab is complicated by rare occurrence of progressive multifocal leukoencephalopathy (PML)…”
Get full text